Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Cresset Targets International Growth with Innovate UK Scaleup Programme

    Oct 19, 2023, 09:05 AM by
    Drug discovery specialists Cresset have joined Innovate UK’s Scaleup Programme for businesses with high growth potential
    Full story
  • New £30m Initiative to Address Global Threat by Accelerating the Pace of Antimicrobial Innovation

    Oct 19, 2023, 09:04 AM by
    Pioneering partnership to drive development of new tests and treatments to tackle deadly antimicrobial resistance, which could otherwise kill 10 million a year by 2050
    Full story
  • CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

    Oct 19, 2023, 09:04 AM by
    Full story
  • CD Genomics Unveils Cutting-Edge CRISPR Screen Sequencing Technology

    Oct 19, 2023, 09:04 AM by
    Full story
  • BOC Sciences at TIDES Europe 2023: Key Chemicals and XDC Platform to Be Exhibited

    Oct 19, 2023, 09:04 AM by
    BOC Sciences will attend "TIDES Europe: Oligonucleotide & Peptide Therapeutics", delivered as a hybrid event from 30 Oct - 1 Nov 2023, in Amsterdam, NL. Its high-yield nucleosides & nucleotides, as well as a newly launched XDC platform, will be exhibited in front of the industry.
    Full story
  • CD Genomics Introduces Cutting-Edge Degradome Sequencing Service Redefining Transcriptomics Research

    Oct 19, 2023, 09:04 AM by
    Full story
  • Biotium Introduces New Highly-Selective Stains For Both Gram-Positive and Gram-Negative Bacteria

    Oct 19, 2023, 09:03 AM by
    Biotium has announced the launch of its breakthrough BactoView™ Dead Stains and BactoView™ Viability Kits.
    Full story
  • LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

    Oct 19, 2023, 09:03 AM by
    LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types.
    Full story
  • Censinet and First Health Advisory Partner to Deliver Comprehensive Cyber Risk Assurance to Health Sector

    Oct 19, 2023, 09:03 AM by
    Partnership Enables Healthcare Organizations to Leverage Unique Risk Advisory Services and Purpose-Built Workflow Automation to Maximize Cyber Risk Reduction
    Full story
  • Inizio Engage launches new global powerhouse learning brand, Nazaré

    Oct 19, 2023, 09:03 AM by
    Full story
  • JPA HEALTH EXPANDS LIFE SCIENCES DIVISION WITH ACQUISITION OF TRUE NORTH SOLUTIONS, INC.

    Oct 19, 2023, 09:03 AM by
    Addition brings together synchronized experts to offer comprehensive predictive analytics, data visualization and AI-driven end-to-end solutions for life sciences, government and non-profit organizations
    Full story
  • Servier partners with Owkin with the aim of discovering and developing AI-driven precision therapeutics

    Oct 18, 2023, 08:59 AM by
    Servier partners with Owkin with the aim of discovering and developing AI-driven precision therapeutics. The multi-year agreement will use Owkin’s sophisticated AI to potentially enable Servier to develop novel therapeutics across various disease areas.
    Full story
  • Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO

    Oct 18, 2023, 08:59 AM by
    Full story
  • Multi-Lab Preclinical Model Aims To Solve The Reproducibility Crisis

    Oct 18, 2023, 01:00 AM by User Not Found
    Bio-IT World| A new preclinical system put to the test by a network of labs to adaptively study a handful of stroke treatments has succeeded in demonstrating that high-quality science is “feasible, practical, and less expensive than doing things the wrong way.”
    Full story
  • Expanding Research Horizons: CD Formulation Unveils its Redesigned Collection of Pharmaceutical Excipients

    Oct 17, 2023, 08:34 AM by
    Full story
  • Unleashing Diamond's Full Potential: Alfa Chemistry's Single Crystalline and Polycrystalline Diamond Transformations

    Oct 17, 2023, 08:34 AM by
    Full story
  • Discovery Park and Researcher partner to support scientific collaboration

    Oct 17, 2023, 08:30 AM by
    Discovery Park, Kent’s thriving life science community, has partnered with scientific content discovery and discussion platform, Researcher, to promote collaboration and facilitate scientific progress.
    Full story
  • ISPE Names Genentech the 2023 Facility of the Year Awards Overall Winner

    Oct 17, 2023, 08:30 AM by
    ISPE has recognized Genentech as the 2023 Facility of the Year Awards (FOYA) Overall Winner for the Clinical Supply Center (CSC) project located in South San Francisco, California, USA.
    Full story
  • Illumina Ordered To Unwind Acquisition Of GRAIL

    Oct 16, 2023, 14:23 PM by User Not Found
    Bio-IT World| The European Commission (EC), under the EU Merger Regulation (EUMR), released a statement last week announcing it has taken restorative measures that require Illumina to unwind its acquisition of GRAIL. The acquisition was completed before the EC provided approval, breaching EU merger control rules.
    Full story
  • OncoDxRx Showcases Advanced Applications of One-Of-A-Kind PGA Test in Taiwan

    Oct 16, 2023, 08:50 AM by
    When cfDNA testing result is negative or patients become unresponsive/resistant to current existing treatment strategy, plasma-based cfmRNA testing (ie., OncoDxRx’s PGA assay) can help clinicians to select the most effective therapy available within 5 days. Particularly in advanced cases of cancer, wait times associated with complex NGS testing of cfDNA can significantly impact a patient’s time to treatment and overall outcome.
    Full story
  • «
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69 (current)
  • 70
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy